Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-12-05 pm EST
50.73 USD   -0.35%
04:08pPfizer asks FDA to approve updated COVID-19 shot for young children
AQ
11:01aUpdates In Co-Pay Assistance And Accumulators Litigation
AQ
10:50aPfizer asks FDA to clear updated COVID shot for kids under 5
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Indonesia to produce China's new COVID vaccine

09/30/2022 | 06:21am EST

Indonesia is the first nation to green light use of the shot.

On Friday (September 30) officials there said they would start producing it in the country.

Known as AWcorna, the vaccine uses the mRNA technology.

Penny Lukito is head of the Indonesia's national food and drug agency:

"The emergency authorization can be given to premier and booster vaccinations for adults."

Lukito said the new drug is over 71% effective against the highly contagious Omicron variant, and over 83% effective against some other strains.

However, there were no details on how the shot will be used in Indonesia.

More than 63% of its population is already fully vaccinated.

The country already uses mRNA vaccines made by Pfizer and others.

But the AWcorna shot has a longer shelf life, which could make it useful in Indonesia and other countries which have poor logistics in remote areas.

STORY: China's new COVID vaccine has won its first national approval for use - but not in China.


ę Reuters 2022
All news about PFIZER, INC.
04:08pPfizer asks FDA to approve updated COVID-19 shot for young children
AQ
11:01aUpdates In Co-Pay Assistance And Accumulators Litigation
AQ
10:50aPfizer asks FDA to clear updated COVID shot for kids under 5
AQ
08:03aPfizer, BioNTech Seek FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Biva..
MT
07:30aPfizer applies for FDA authorization for Omicron-retooled vaccine booster in kids under..
RE
07:03aPfizer-BioNTech Seek US FDA Emergency Use Nod For Bivalent COVID-19 Jab In Young Childr..
MT
06:56aPfizer applies for FDA authorization for Omicron-retooled vaccine booster in under-5 ki..
RE
12/02Pfizer bets $2.5 bln on European output boost
RE
12/02Pfizer to Spend More Than $2.5 Billion to Expand Plants in Belgium, Ireland
MT
12/02Vaxxinity's Phase 3 COVID-19 Vaccine Trial Meets Endpoints
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 100 B - -
Net income 2022 33 621 M - -
Net cash 2022 5 430 M - -
P/E ratio 2022 8,93x
Yield 2022 3,18%
Capitalization 286 B 286 B -
EV / Sales 2022 2,80x
EV / Sales 2023 3,50x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 50,73 $
Average target price 53,78 $
Spread / Average Target 6,00%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-13.78%285 774
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
MERCK & CO., INC.43.58%278 995